Non seulement, cette étude de cohorte prospective confirme qu'un traitement d'arrêt du tabac fondé sur des preuves dans les 6 mois qui suivent un diagnostic de cancer optimise les avantages en termes ...
Since launching AVISE CTD in 2012, Exagen has produced an extensive body of peer-reviewed literature supporting the test’s clinical validity and utility. These publications and the 1,000,000 th ...
Residents of Olympia Fields and Chicagoland’s surrounding southern suburban communities can now access quality end-of-life care at the VITAS Healthcare Inpatient Hospice Unit at Franciscan Health ...
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T ™) products for cancer and autoimmune disease, today ...
The new promising data presented by Martin Forster, M.D., Ph.D., at the ESMO Immuno-Oncology (IO) Annual Congress 2024 includes strong overall survival, progression-free survival, and durability. This ...
The presentation highlights XORTX recent pioneering discoveries in the field of Autosomal Dominant Polycystic Kidney Disease (“ADPKD”), and recent peer-reviewed, independent, published research ...
BrainsWay Deep TMS is not currently cleared by the FDA for the safe or effective treatment of AUD.
ZTlido ® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company. Gloperba ® is the subject of an exclusive, transferable license to use the ...
In allergen-driven models of atopic dermatitis, subcutaneous (SQ) administration of ‘1104 demonstrated comparable performance to intravenous administration (IV) In multiple preclinical models ...
Mr. Springate is the second former AIM executive to support the Kellner Group’s efforts in the past week, following the announcement that Ampligen co-founder and former AIM CEO Dr. Carter agreed to ...
Il faudrait faire du sport tous les jours, pour bénéficier d’une performance cognitive toujours au top, conclut cette équipe de neurologues de l’University College London. Si les effets bénéfiques de ...
Dr. Doberstein brings extensive biotech leadership experience as the company advances its AI-powered pipeline into Phase 2 for immune-mediated inflammatory disorders GUILFORD, Conn., Dec. 12, 2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback